Cuál es el precio por Clovis Oncology, Inc. (C6O)

Precio por Clovis Oncology, Inc. (C6O) es de$0.10794012

Cuál es la capitalización de mercado por Clovis Oncology, Inc. (C6O)

Capitalización de mercado por Clovis Oncology, Inc. (C6O) es $15.65M

Clovis Oncology, Inc. (C6O) Historial de Precios

Clovis Oncology, Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of anti-cancer agents, serving markets in the United States, Europe, and globally. Its flagship commercial product in the U.S. is Rubraca (rucaparib), an oral small molecule designed to inhibit poly ADP-ribose polymerase. This treatment is indicated for recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer, as well as for metastatic castration-resistant prostate cancer. In Europe, Rubraca is offered for recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer. The company's pipeline includes lucitanib, an investigational angiogenesis inhibitor that targets vascular endothelial growth factor receptors 1 through 3 (VEGFR 1-3), platelet-derived growth factor receptors alpha and beta (PDGFRa/ß), and fibroblast growth factor receptors 1 through 3 (FGFR 1-3). Also under development is FAP-2286, an investigational peptide-targeted radionuclide therapy and imaging agent that specifically acts upon fibroblast activation protein. Rubraca is distributed through a select network of specialty distributors and pharmacies, which then supply the medication to patients and healthcare providers. Clovis Oncology has established strategic collaborations, including license agreements with Pfizer Inc., AstraZeneca UK Limited, Advenchen Laboratories LLC, and 3B Pharmaceuticals GmbH. The company also maintains a clinical collaboration with Bristol Myers Squibb Company and a partnership with Foundation Medicine, Inc. Founded in 2009, Clovis Oncology, Inc. is headquartered in Boulder, Colorado.

Año	Rendimiento
2022	-92.16%
2021	-41.81%
2020	-57.55%
2019	0.00%

Año

Rendimiento

2022

-92.16%

2021

-41.81%

2020

-57.55%

2019

0.00%

Empresa	Precio de la acción	Cambio 1a%	País
Vertex Pharmaceuticals Incorporated VRTX.US	$527.89	35.40%	US
Argenx SE ARGX.US	$996.61	50.70%	NL
CSL Limited CSL.AX	$111.31	-36.83%	AU
Lonza Group AG LONN.SW	$735.86	6.87%	CH
UCB S.A. UCB.BR	$257.75	13.01%	BE

Empresa

Precio de la acción

Cambio 1a%

País